Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)Business Wire • 09/27/22
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid TumorsBusiness Wire • 09/26/22
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New IndicationZacks Investment Research • 09/20/22
Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal CancerBusiness Wire • 09/19/22
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial CancerBusiness Wire • 09/12/22
Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial CancerPRNewsWire • 09/12/22
Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) CongressBusiness Wire • 09/07/22
Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness Wire • 09/07/22
These eight health-care stocks can keep you invested in the market with less worryMarket Watch • 08/02/22
Seagen Inc. (SGEN) CEO Roger Dansey on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/29/22